Get the Stockscreener App
0.8746
4.93%
-0.0454
Citius Pharmaceuticals Inc stock is traded at $0.8746, with a volume of 624.14K.
It is down -4.93% in the last 24 hours and up +11.14% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
See More
Previous Close:
$0.92
Open:
$0.909
24h Volume:
624.14K
Relative Volume:
0.32
Market Cap:
$8.76M
Revenue:
-
Net Income/Loss:
$-39.14M
P/E Ratio:
-0.1465
EPS:
-5.97
Net Cash Flow:
$-28.20M
1W Performance:
+2.77%
1M Performance:
+11.14%
6M Performance:
-68.65%
1Y Performance:
-94.43%
1-Day Range:
$0.855
$0.9184
1-Week Range:
$0.85
$2.38
52-Week Range:
$0.65
$26.25
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.8746 | 8.76M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Upgrade | D. Boral Capital | Hold → Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - The Victoria Advocate
Citius Pharmaceuticals Closes $6M Securities Offering - TipRanks
After Major Oncology Conference, All Eyes Turn to Industry Innovation - Quantisnow
Citius Pharmaceuticals Announces Closing Of Registered Direct Offering Of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - marketscreener.com
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules | CTXR Stock News - GuruFocus
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits - Quantisnow
Citius Pharmaceuticals Secures $15.8M Financing Deal: What This Means for LYMPHIR Commercialization - Stock Titan
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - Longview News-Journal
Citius Pharma secures $6 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharmaceuticals (CTXR) Target Price Reduced Amid Fundrais - GuruFocus
Citius Pharmaceuticals (CTXR) Target Price Reduced Amid Fundraising Efforts | CTXR Stock News - GuruFocus
Citius Pharmaceuticals Stock Is Falling Tuesday: What's Going On? - Benzinga
Citius Pharmaceuticals (CTXR) Announces $6 Million Direct Offeri - GuruFocus
Citius Pharmaceuticals (CTXR) Announces $6 Million Direct Offering - GuruFocus
Citius Pharmaceuticals (CTXR) Price Target Lowered, Rating Maintained | CTXR Stock News - GuruFocus
Citius Pharmaceuticals announces registered direct offering of $15.8 million - MSN
Citius Pharma secures $6 million in stock offering - Investing.com Australia
Citius Pharmaceuticals (CTXR) Announces Stock and Warrant Offeri - GuruFocus
Citius Pharmaceuticals (CTXR) Announces Stock and Warrant Offering | CTXR Stock News - GuruFocus
Citius Pharma Announces Direct Offering - Nasdaq
Citius Pharmaceuticals Announces a Registered Direct Offering of - GuruFocus
Citius Pharmaceuticals (NASDAQ:CTXR) Given “Buy” Rating at D. Boral Capital - Defense World
Citius Pharmaceuticals expands authorized shares By Investing.com - Investing.com Nigeria
Citius Oncology partners with Cardinal Health for LYMPHIR distribution By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals expands authorized shares - Investing.com
Citius Pharmaceuticals Stock Is Soaring Monday: What's Going On? - Benzinga
Citius Pharmaceuticals (CTXR) Receives Continued Buy Rating from Analyst | CTXR Stock News - GuruFocus
Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR - Nasdaq
Citius Oncology stock soars on distribution deal By Investing.com - Investing.com Nigeria
Citius Oncology stock soars on distribution deal - Investing.com
Cardinal Health (CAH) Partners with Citius Oncology for LYMPHIR Distribution | CAH Stock News - GuruFocus
Citius Oncology partners with Cardinal Health for LYMPHIR distribution - Investing.com
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health | CTXR Stock News - GuruFocus
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health - PR Newswire
Squarepoint Ops LLC Sells 609,711 Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Northern Trust Corp Sells 306,583 Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - mx.advfn.com
Citius Pharmaceuticals Issues $1M Promissory Note to Pagoda - TipRanks
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives $54.50 Consensus Price Target from Brokerages - Defense World
Why Shares of SoundHound AI Are Soaring Today - The Globe and Mail
Citius Pharmaceuticals (NASDAQ:CTXR) Cut to Hold at Maxim Group - Defense World
Maxim Group Downgrades Citius Pharmaceuticals (CTXR) - MSN
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Citius Pharmaceuticals (CTXR) Downgraded to Hold by Maxim Group - GuruFocus
Maxim Downgrades Citius Oncology to Hold From Buy - marketscreener.com
Citius Pharmaceuticals (CTXR) Downgraded to Hold by Maxim | CTXR Stock News - GuruFocus
Citius Pharmaceuticals (NASDAQ:CTXR) Earns Buy Rating from D. Boral Capital - Defense World
Citius Pharmaceuticals (CTXR) Receives Continued "Buy" Rating fr - GuruFocus
Citius Pharmaceuticals Reports Q1 2025 Earnings and Strategic Developments - TipRanks
Citius Pharmaceuticals (CTXR) Receives Continued "Buy" Rating from Analyst | CTXR Stock News - GuruFocus
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):